arrow
L

Luana Fianchi

Fondazione Policlinico Universitario A. Gemelli
H指数:41
被引数:6,738

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-Life Study on Gilteritinib-Related Infections (GilteRInf): An Italian SEIFEM Study

Gilteritinib相关感染的Real-Life研究(GilteRInf):一项意大利SEIFEM研究

2026-07-280
OAAI
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience

司妥昔单抗在冷凝集素病中的安全性与有效性:一项真实世界国际经验

2026-04-160
OA
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

根据SIE/SIES/GITMO标准对治疗相关和aml-mrc接受CPX-351的适应性分类的影响。

2025-12-110
OAAI
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study
2024-10-310
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA
2023-09-014
OAAI
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

luspatercept的真实世界疗效和安全性以及对具有环状成纤维细胞的低风险骨髓增生异常综合征患者的反应预测因素

2023-05-246
OAAI
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

tixagevimab/cilgavimab对血液系统恶性肿瘤和新型冠状病毒肺炎患者的被动暴露前预防接种: EPICOVIDEHA注册表中的配对分析

2023-04-0113
OAAI
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

AVALON: 低甲基化药物联合维尼托克对新诊断或复发/难治性急性髓系白血病患者的现实疗效的意大利队列研究

CANCER
IF5.1
2023-01-2421
OAAI
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
2022-09-0710
OAAI
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
2022-07-1914
OAAI
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
2022-05-1228
OAAI